<table>
<thead>
<tr>
<th>Guideline Page and Request</th>
<th>Panel Discussion</th>
<th>Vote</th>
<th>References</th>
</tr>
</thead>
</table>
| **ESOPH-F 3 of 14**  
Internal request:  
Review the recent clinical trial data and category of evidence for “fluorouracil and irinotecan” as a preferred regimen for first-line treatment of metastatic or locally advanced esophageal and EGJ cancers.  
Based on the discussion and review of data, the panel consensus was to change the recommendation for “fluorouracil and irinotecan” from category 2A to category 1 under the list of preferred regimens for first-line therapy for metastatic or locally advanced cancer. | Yes 15 | No 0 | Abstain 6 | Guimbaud R, Louvet C, Ries P, et al. Prospective, Randomized, Multicenter, Phase III Study of Fluorouracil, Leucovorin, and Irinotecan Versus Epirubicin, Cisplatin, and Capecitabine in Advanced Gastric Adenocarcinoma: A French Intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) Study. J Clin Oncol 2014;32:3520-3526 |
| Internal request:  
Review the category of evidence for single-agent docetaxel, paclitaxel, and irinotecan as preferred regimens for second-line therapy for metastatic or locally advanced esophageal and EGJ cancers.  
Based on the discussion and review of data, the panel consensus was to change the recommendation for docetaxel, paclitaxel, and irinotecan from category 2A to category 1 under the list of preferred regimens for second-line therapy for metastatic or locally advanced cancer.  
- Docetaxel  
- Paclitaxel  
- Irinotecan | Yes 15  
No 14  
| Internal request:  
Review the category of evidence and consensus for “ramucirumab and paclitaxel” as a preferred second-line regimen. Consider changing the recommendation to category 1 for EGJ adenocarcinoma and adding it as a treatment option for esophageal adenocarcinoma based on the recent publication of data from the RAINBOW trial.  
Based on the discussion and review of data the panel consensus was to make the following changes for “ramucirumab and paclitaxel” under the list of preferred regimens for second-line therapy for metastatic or locally advanced cancer:  
- Change from category 2A to category 1 for EGJ adenocarcinoma  
- Add ramucirumab and paclitaxel with a category 2A recommendation for esophageal adenocarcinoma. | Yes 15  
No 14  
<table>
<thead>
<tr>
<th>Guideline Page and Request</th>
<th>Panel Discussion</th>
<th>Vote</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>ESOPH-F 3 of 14 Internal request: Consider adding single-agent ramucirumab as a treatment option for the treatment of adenocarcinoma of the esophagus.</td>
<td>Based on the discussion and review of data from the REGARD trial, the panel consensus was to add ramucirumab as a treatment option for adenocarcinoma of the esophagus under the list of preferred regimens for second-line therapy for metastatic or locally advanced cancer with a category 2A recommendation</td>
<td>YES 14</td>
<td>NO 1</td>
</tr>
</tbody>
</table>